TNF and myeloid sarcoma: TNF-α inhibitors have been proposed as a treatment in MS based on the key role played by the TNF-α cytokine in MS pathogenesis; however, multiple studies have shown that not only did TNFα inhibitors fail to stop disease progress, but they even caused symptom exacerbation [164].